Armune BioScience, Inc.
Armune BioScience was formed to develop and commercialize high value, protein signature-based diagnostic tests for prostate, lung and breast cancers that will allow physicians and patients to make better treatment decisions. Prostate cancer is the most prevalent cancer affecting men in the U.S. and is the second leading cause of cancer deaths in men in the U.S.[1] It is also a major cause of death in Europe, with the U.S. and Western Europe accounting for 51% of the prostate cancer deaths in the world in 2005. The PSA (Prostate Specific Antigen) test is the primary prostate cancer diagnostic test used today. The PSA test has good sensitivity but poor specificity resulting in many false positives and unnecessary biopsies.
Lung cancer is the leading cause of cancer deaths and there are no lung cancer diagnostic blood tests available today, so this represents a significant unmet market opportunity.
Breast cancer is the second leading cause of cancer deaths in women today (after lung cancer) and is the most common cancer among women. Although breast cancer rates are rising in many western countries, deaths from the disease have decreased in some countries as a result of improved screening (mammography) and treatment. However, there are no serum-based breast cancer diagnostic tests available today.